Purpose Our aim was to analyze and validate the prognostic impact of the novel
International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/…

Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1
immunotherapy in pulmonary adenocarcinoma and in clinically unselected cohorts of so-…

Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are
driven by less common genomic alterations, registries provide complementary information on …

Introduction Comorbidities significantly influence the clinical course of idiopathic pulmonary
fibrosis (IPF). However, their prognostic impact is not fully understood. We therefore aimed to …

Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry
(IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small …

The majority of patients with solid malignancies die from metastatic burden. However, our
current understanding of the mechanisms and resulting patterns of dissemination is limited. …

Tumor spread, in general, is the most important factor determining outcome in almost all
malignant tumors. Lung tumors are unique with respect to potential routes for tumor …

Introduction It can be difficult to distinguish between a second primary and a metastasis in
patients with lung cancer who have more than one pulmonary site of cancer. Methods A …

Vasogenic edema is one of the most serious clinical problems in brain tumors and tightly
connected to water shifts between the different fluid compartments in the brain. Aquaporin …

Introduction Patients with lung cancer who harbor multiple pulmonary sites of disease have
been challenging to classify; a subcommittee of the International Association for the Study of …